GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tegileridine   Click here for help

GtoPdb Ligand ID: 13434

Synonyms: Asut® | Embodiment 1 [US11111236B2] | example 19 [US20200054594A1] | SHR-8554 | SHR8554
Approved drug
tegileridine is an approved drug (China (2024))
Compound class: Synthetic organic
Comment: Tegileridine (SHR8554) is an intravenously bioactive μ-opioid receptor agonist. It selectively activates the G protein-coupled pathway [2] and only weakly activates β-arrestin 2 recruitment. G protein-coupling bias is predicted to limit side effects such as respiratory depression and gastrointestinal inhibition.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 42.85
Molecular weight 434.61
XLogP 3.21
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCO[C@H]1CC[C@@H](C2=C1C=CC=C2)NCC[C@]3(CCOC4(CCCC4)C3)C5=NC=CC=C5
Isomeric SMILES CCO[C@H]1CC[C@@H](C2=CC=CC=C12)NCC[C@]3(CCOC4(C3)CCCC4)C5=CC=CC=N5
InChI InChI=1S/C28H38N2O2/c1-2-31-25-13-12-24(22-9-3-4-10-23(22)25)29-19-16-27(26-11-5-8-18-30-26)17-20-32-28(21-27)14-6-7-15-28/h3-5,8-11,18,24-25,29H,2,6-7,12-17,19-21H2,1H3/t24-,25-,27+/m0/s1
InChI Key YUMLNLMFBWBKSK-OHSXHVKISA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
The Chinese drug regulator (NMPA) approved tegileridine in January 2024 [1,3]. It is indicated to treat moderate to severe postoperative (abdominal surgery) pain.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04766463 A Clinical Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery. Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT05470049 A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery. Phase 2 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT05375305 A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery Phase 2/Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd.